William Blair initiated coverage of Lifecore (LFCR) with an Outperform rating. Minimum volume commitments from Alcon (ALC) represent “a solid foundation for Lifecore’s achievable midterm revenue guide,” says the analyst, who projects revenue will grow at an 11.6% compound annual rate from FY25 to FY28, consistent with Lifecore’s guidance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Lifecore Biomedical’s Promising Growth Trajectory: Buy Rating with 34% Upside Potential
- Lifecore appoints Salus as chief legal, administration officer
- Lifecore pullback creates attractive entry point, says Craig-Hallum
- Lifecore Biomedical’s Earnings Call: Strategic Optimism Amid Challenges
- China announces retaliatory tariffs, U.S. unemployment rises: Morning Buzz